T cell lymphoma and secondary primary malignancy risk after commercial CAR T cell therapyGuido Ghilardi, Marco Ruella, Luca Paruzzo et al.|Nature Medicine|2024Cited by 254
CD5 deletion enhances the antitumor activity of adoptive T cell therapiesRuchi P. Patel, Patrizia Porazzi, Guido Ghilardi et al.|Science Immunology|2024Cited by 45
The BTLA–HVEM axis restricts CAR T cell efficacy in cancerPuneeth Guruprasad, Marco Ruella, Alberto Carturan et al.|Nature Immunology|2024Cited by 41